Shares of Mylan N.V. (NASDAQ:MYL) advanced to $44.77. The price had gained 0.54% or 0.24 points intraday. The latest trading session witnessed $27.77 million in upticks and $43 million in downticks, resulting in net money flow of (-15.23) million. The up/down ratio for the day stood at 0.65. On a weekly scale, the price has seen a change of 0.56%. From the trading data available, it was disclosed that a block trade of negative money flow worth $(-14.81) million occurred during the day. $4.62 million in uptick and $19.43 million in downtick were the highlight of the block transaction which had an up/down ratio of 0.24.
Currently the company Insiders own 0.71% of Mylan N.V. shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -13.09% . Institutional Investors own 66.47% of Mylan N.V. shares. During last six month period, the net percent change held by insiders has seen a change of -11.04%. On the companys insider trading activities, Maroon Joseph C Md, director of Mylan N.V., had purchased 1,670 shares on June 3, 2016. The total value of the transaction was $75,067. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Mylan N.V. (NASDAQ:MYL) : On Monday heightened volatility was witnessed in Mylan N.V. (NASDAQ:MYL) which led to swings in the share price. The stock opened for trading at $44.15 and hit $45.37 on the upside , eventually ending the session at $44.77, with a gain of 0.54% or 0.24 points. The heightened volatility saw the trading volume jump to 4,893,113 shares. The 52-week high of the share price is $73.91 and the company has a market cap of $22,759 million. The 52-week low of the share price is at $37.59 .
Many analysts have stated their opinion on the company shares. In a research note released to the investors, Leerink Swann maintains its rating on Mylan N.V. (NASDAQ:MYL).The analysts at the brokerage house have a current rating of Outperform on the shares. In a recent information released to the investors, Leerink Swann lowers the new price target from $53 per share to $51 per share. The rating by the firm was issued on May 4, 2016.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.